NCT01687699

Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 157 (actual)
• Sponsor: Dialysis Outcomes Heart Failure Aldactone Study Group · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: —

Summary

Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis (HD) patients. In the present study, we assess whether low-dose spironolactone treatment reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in HD patients. The investigators' hypothesis is that aldosterone receptor blockade by spironolactone reduces the risk of both CCV morbidity and death among HD patients.

Conditions

• End-stage Renal Failure

Interventions

Type	Name	Description
DRUG	Spironolactone

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-12-01
• First posted: 2012-09-19
• Last updated: 2012-09-19

Locations

1 site across 1 country: Japan